首页> 美国卫生研究院文献>Annals of Oncology >A multicenter randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG

【2h】

A multicenter randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG

机译：单剂卡铂与单药卡铂作为晚期卵巢癌的一线化疗的多中心随机对照临床研究：SGGCG（SCOTROC 4）和ANZGOG代表GCIG进行的研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundThe aim of the study is to demonstrate that intrapatient dose escalation of carboplatin would improve the outcome in ovarian cancer compared with flat dosing.

机译：背景研究的目的是证明与常规给药相比，卡铂患者的剂量增加将改善卵巢癌的预后。

著录项

期刊名称 Annals of Oncology
作者
S. Banerjee; G. Rustin; J. Paul; C. Williams; S. Pledge; H. Gabra; G. Skailes; A. Lamont; A. Hindley; G. Goss; E. Gilby; M. Hogg; P. Harper; E. Kipps; L-A Lewsley; M. Hall; P. Vasey; S. B. Kaye;
展开▼
作者单位

展开▼
年(卷),期 -1(24),3
年度 -1
页码 679–687
总页数 17
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
carboplatin dose escalation myelosuppresssion ovarian cancer;

机译：卡铂;剂量增加;骨髓抑制;卵巢癌;

相似文献

外文文献
中文文献

1. A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: An SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG [J] . BanerjeeS., RustiG., PaulJ., Annals of oncology: official journal of the European Society for Medical Oncology . 2013,第3期

机译：单一剂量卡铂与门诊剂量递增作为晚期卵巢癌一线化疗的多中心随机对照试验：一项SGCTG（SCOTROC 4）和ANZGOG代表GCIG进行的研究
2. Paclitaxel-carboplatin-gemcitabine (TCG) as first-line treatment of ovarian cancer: a prospective multicenter phase II study (AGO-OVAR 8) followed by a prospectively randomized phase III GCIG Intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102) co [J] . Bois A, Sehouli J, Lund B, International journal of gynecological cancer: official journal of the International Gynecological Cancer Society . 2005,第Suppla3期

机译：紫杉醇-卡铂-吉西他滨（TCG）作为卵巢癌的一线治疗：前瞻性多中心II期研究（AGO-OVAR 8），然后进行前瞻性随机III期GCIG组间研究（AGO-OVAR 9，GINECO-TCG，NSGO） -OC-0102）公司
3. Sequential cycles of high-dose chemotherapy with dose escalation of carboplatin with or without paclitaxel supported by G-CSF mobilized peripheral blood progenitor cells: a phase I/II study in advanced ovarian cancer. [J] . Wandt H, Birkmann J, Denzel T, Bone marrow transplantation . 1999,第8期

机译：在有或没有紫杉醇的情况下，大剂量化疗加卡铂加或不加紫杉醇的顺序周期，由G-CSF动员的外周血祖细胞进行：I / II期研究在晚期卵巢癌中。
4. Combination of first-line chemotherapy with Kanglaite injections versus first-line chemotherapy alone for advanced non-small-cell lung cancer: study protocol for an investigator-initiated multicenter open-label randomized controlled trial [O] . Ruike Gao, Ying Zhang, Wei Hou, 2021

机译：单线化疗与康拉特注射的组合对先进的非小细胞肺癌的一线化疗：研究方案的研究方案 - 发起多中心开放标签随机对照试验
5. A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG [O] . S. Banerjee, G. Rustin, J. Paul, 2013

机译：多中心，随机试验的平坦剂量与体内剂量剂量升级单孕术治疗，单人蛋白癌为一线化疗，用于晚期卵巢癌：SGCTG（SCOTROC 4）和Anzgog代表GCIG研究

A multicenter randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG

摘要

著录项

相似文献

相关主题

期刊订阅